Clinical utility of viscoelastic tests of coagulation in patients with liver disease

Liver International

Volumn 33, Issue 7, 2013, Pages 961-974

  Mallett, Susan V ^a   Chowdary, Pratima ^a   Burroughs, Andrew K ^a  

^a ROYAL FREE LONDON NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

Coagulation and liver disease; Thromboelastography; Thromboelastometry

Indexed keywords

ALPHA 2 ANTIPLASMIN; ANTICOAGULANT AGENT; ANTITHROMBIN; BLOOD CLOTTING FACTOR 13; ENOXAPARIN; FIBRINOGEN; FRESH FROZEN PLASMA; PROCOAGULANT; PROTEIN C; PROTEIN S; THROMBIN; THROMBOMODULIN; THROMBOPLASTIN; TISSUE PLASMINOGEN ACTIVATOR; VON WILLEBRAND FACTOR;

ANTICOAGULATION; BLEEDING; BLOOD CLOTTING; BLOOD CLOTTING DISORDER; BLOOD CLOTTING TEST; CHRONIC LIVER DISEASE; COAGULATION VISCOELASTIC TEST; DISEASE ASSOCIATION; FIBRINOLYSIS; HEMOSTASIS; HUMAN; HYPERCOAGULABILITY; IDIOPATHIC THROMBOCYTOPENIC PURPURA; INTERNATIONAL NORMALIZED RATIO; LIVER BIOPSY; LIVER DISEASE; LIVER FUNCTION; LIVER TRANSPLANTATION; NONALCOHOLIC FATTY LIVER; PORTAL HYPERTENSION; PORTAL VEIN; PROTHROMBIN TIME; REVIEW; SCORING SYSTEM; SYSTEMATIC REVIEW; SYSTEMATIC REVIEW (TOPIC); TENSILE STRENGTH; THROMBELASTOMETRY; THROMBOCYTE COUNT; THROMBOCYTE FUNCTION; THROMBOCYTE TRANSFUSION; THROMBOCYTOPENIA; THROMBOELASTOGRAPHY; TRANSFUSION RELATED ACUTE LUNG INJURY;

COAGULATION AND LIVER DISEASE; THROMBOELASTOGRAPHY; THROMBOELASTOMETRY;

BLOOD COAGULATION; BLOOD VISCOSITY; ELASTICITY; FIBRINOLYSIS; HUMANS; LIVER DISEASES; THROMBELASTOGRAPHY; THROMBIN;

EID: 84880147160     PISSN: 14783223     EISSN: 14783231     Source Type: Journal    
DOI: 10.1111/liv.12158     Document Type: Review

References (121)

1. Mannucci PM. Abnormal hemostasis tests and bleeding in chronic liver disease: Are they related? No. J Thromb Haemost 2006; 4: 721-3.
2. Tripodi A, Mannucci PM. Abnormalities of hemostasis in chronic liver disease: reappraisal of their clinical significance and need for clinical and laboratory research. J Hepatol 2007; 46: 727-33.
3. Tripodi A, Salerno F, Chantarangkul V, et al. Evidence of normal thrombin generation in cirrhosis despite abnormal conventional coagulation tests. Hepatology 2005; 41: 553-8.
4. Sogaard KK, Horvath-Puho E, Gronbaek H, et al. Risk of venous thromboembolism in patients with liver disease: a nationwide population-based case-control study. Am J Gastroenterol 2009; 104: 96-101.
5. Shore-Lesserson L, Manspeizer HE, DePerio M, et al. Thromboelastography-guided transfusion algorithm reduces transfusions in complex cardiac surgery. Anesth Analg 1999; 88: 312-19.
6. Schochl H, Frietsch T, Pavelka M, Jambor C. Hyperfibrinolysis after major trauma: differential diagnosis of lysis patterns and prognostic value of thrombelastometry. J Trauma 2009; 67(1): 125-31.
7. Kashuk JL, Moore EE, Sabel A, et al. Rapid thrombelastography (r-TEG) identifies hypercoagulability and predicts thromboembolic events in surgical patients. Surgery 2009; 146: 764-74.
8. Kang YG, Martin DJ, Marquez J, et al. Intraoperative changes in blood coagulation and thrombelastographic monitoring in liver transplantation. Anesth Analg 1985; 64: 888-96.
9. Tripodi A, Primignani M, Chantarangkul V, et al. The coagulopathy of cirrhosis assessed by thromboelastometry and its correlation with conventional coagulation parameters. Thromb Res 2009; 124: 132-6.
10. Basili S, Raparelli V, Violi F. The coagulopathy of chronic liver disease: is there a causal relationship with bleeding? Yes. Eur J Intern Med 2010; 21: 62-4.
11. Dabbagh O, Oza A, Prakash S, Sunna R, Saettele TM. Coagulopathy does not protect against venous thromboembolism in hospitalized patients with chronic liver disease. Chest 2010; 137: 1145-9.
12. Tripodi A, Mannucci PM. The coagulopathy of chronic liver disease. New Eng J Medicine 2011; 365: 147-56.
13. Massicotte L, Beaulieu D, Thibeault L, et al. Coagulation defects do not predict blood product requirements during liver transplantation. Transplantation 2008; 85: 956-62.
14. Lisman T, Caldwell SH, Burroughs AK, et al. Hemostasis and thrombosis in patients with liver disease: the ups and downs. J Hepatol 2010; 53: 362-71.
15. Northup PG, Caldwell SH. New concepts of coagulation and bleeding in liver disease. Intern Emerg Med 2010; 5: 3-6.
16. Violi F, Basili S, Raparelli V, et al. Patients with liver cirrhosis suffer from primary haemostatic defects? Fact or fiction? J Hepatol 2011; 55: 1415-27.
17. Ben-Ari Z, Panagou M, Patch D, et al. Hypercoagulability in patients with primary biliary cirrhosis and primary sclerosing cholangitis evaluated by thrombelastography. J Hepatol 1997; 26: 554-9.
18. Pihusch R, Rank A, Gohring P, et al. Platelet function rather than plasmatic coagulation explains hypercoagulable state in cholestatic liver disease. J Hepatol 2002; 37: 548-55.
19. British Committee for Standards in Haematology: Blood Transfusion Task Force England. Guidelines for the use of platelet transfusions. Br J Haematol 2003; 122: 10-23.
20. Rockey DC, Caldwell SH, Goodman ZD, Nelson RC, Smith AD. Liver biopsy. Hepatology 2009; 49: 1017-44.
21. Tripodi A, Primignani M, Chantarangkul V, et al. Thrombin generation in patients with cirrhosis: the role of platelets. Hepatology 2006; 44: 440-5.
22. Giannini EG, Greco A, Marenco S, et al. Incidence of bleeding following invasive procedures in patients with thrombocytopenia and advanced liver disease. Clin Gastroenterol Hepatol 2010; 8: 899-902.
23. Afdhal N, McHutchison J, Brown R, et al. Thrombocytopenia associated with chronic liver disease. J Hepatol 2008; 48: 1000-7.
24. Blake JC, Sprengers D, Grech P, et al. Bleeding time in patients with hepatic cirrhosis. BMJ 1990; 301: 12-5.
25. Gatt A, Riddell A, Calvaruso V, et al. Enhanced thrombin generation in patients with cirrhosis-induced coagulopathy. J Thromb Haemost 2010; 8: 1994-2000.
26. Dahlback B. Progress in the understanding of the protein C anticoagulant pathway. Int J Hematol 2004; 79: 109-16.
27. Huntington JA. Mechanisms of glycosaminoglycan activation of the serpins in hemostasis. J Thromb Haemost 2003; 1: 1535-49.
28. Tripodi A, Caldwell SH, Hoffman M, Trotter JF, Sanyal AJ. Review article: the prothrombin time test as a measure of bleeding risk and prognosis in liver disease. Aliment Pharmacol Ther 2007; 26: 141-8.
29. Segal H, Cottam S, Potter D, Hunt BJ. Coagulation and fibrinolysis in primary biliary cirrhosis compared with other liver disease and during orthotopic liver transplantation. Hepatology 1997; 25: 683-8.
30. Stravitz RT, Lisman T, Luketic VA, et al. Acute liver injury/failure (ALI/ALF) results in balanced hemostasis despite elevated INR. Hepatology 2010; 52: 1082A-3A.
31. Ng VL. Liver disease, coagulation testing, and hemostasis. Clin Lab Med 2009; 29: 265-82.
32. Segal JB, Dzik WH. Paucity of studies to support that abnormal coagulation test results predict bleeding in the setting of invasive procedures: an evidence-based review. Transfusion 2005; 45: 1413-25.
33. Auzinger G, O'Callaghan GP, Bernal W, Sizer E, Wendon JA. Percutaneous tracheostomy in patients with severe liver disease and a high. Crit Care 2007; 11: R110.
34. Ewe K. Bleeding after liver biopsy does not correlate with indices of peripheral coagulation. Dig Dis Sci 1981; 26: 388-93.
35. Benson AB, Austin GL, Berg M, et al. Transfusion-related acute lung injury in ICU patients admitted with gastrointestinal bleeding. Intensive Care Med 2010; 36: 1710-17.
36. Dupont J, Messiant F, Declerck N, et al. Liver transplantation without the use of fresh frozen plasma. Anesth Analg 1996; 83: 681-6.
37. Porte RJ, Lisman T, Tripodi A, Caldwell SH, Trotter JF. Coagulation Liver Dis Study Group. The International Normalized Ratio (INR) in the MELD Score: problems and solutions. Am J Transplant 2010; 10: 1349-53.
38. Mann KG. Thrombin formation. Chest 2003; 3(Suppl): 4S-10S.
39. Stanworth SJ, Brunskill SJ, Hyde CJ, McClelland DBL, Murphy MF. Is fresh frozen plasma clinically effective? A systematic review of randomized controlled trials. Br J Haematol 2004; 126: 139-52.
40. Murad MH, Stubbs JR, Gandhi MJ, et al. The effect of plasma transfusion on morbidity and mortality: a systematic review and meta-analysis. Transfusion 2010; 50: 1370-83.
41. Tripodi A, Chantarangkul V, Primignani M, et al. Thrombin generation in plasma from patients with cirrhosis supplemented with normal plasma: considerations on the efficacy of treatment with fresh-frozen plasma. Intern Emerg Med 2012; 7: 139-44.
42. Hron G, Kollars M, Binder BR, Eichinger S, Kyrle PA. Identification of patients at low risk for recurrent venous thromboembolism by measuring thrombin generation. JAMA 2006; 296: 397-402.
43. Besser M, Baglin C, Luddington R, van Hylckama Vlieg A, Baglin T. High rate of unprovoked recurrent venous thrombosis is associated with high thrombin-generating potential in a prospective cohort study. J Thromb Haemost 2008; 6: 1720-5.
44. Tripodi A, Legnani C, Chantarangkul V, et al. High thrombin generation measured in the presence of thrombomodulin is associated with an increased risk of recurrent venous thromboembolism. J Thromb Haemost 2008; 6: 1327-33.
45. van Veen JJ, Gatt A, Makris M. Thrombin generation testing in routine clinical practice: are we there yet? Br J Haematol 2008; 142: 889-903.
46. Schols SEM, Lance MD, Feijge MAH, et al. Impaired thrombin generation and fibrin clot formation in patients with dilutional coagulopathy during major surgery. Thromb Haemost 2010; 103: 318-28.
47. Lisman T, Bakhtiari K, Pereboom IT, et al. Normal to increased thrombin generation in patients undergoing liver transplantation despite prolonged conventional coagulation tests. J Hepatol 2010; 52: 355-61.
48. Hemker HC, Giesen P, Al Dieri R, et al. Calibrated automated thrombin generation measurement in clotting plasma. Pathophysiol Haemost Thromb 2003; 33: 4-15.
49. Hezard N, Bouaziz-Borgi L, Remy MG, Florent B, Nguyen P. Protein C deficiency screening using a thrombin-generation assay. Thromb Haemost 2007; 97: 165-6.
50. Northup PG, McMahon MM, Ruhl AP, et al. Coagulopathy does not fully protect hospitalized cirrhosis patients from peripheral venous thromboembolism. Am J Gastroenterol 2006; 101: 1524-8. quiz 680.
51. Assis DN, Schilsky ML. Testing and management of thrombocytopenia and coagulopathy in the pre- and postliver transplant patient. Minerva Gastroenterol Dietol 2010; 56: 331-43.
52. Hoffman M, Monroe DM, 3rd. A cell-based model of hemostasis. Thromb Haemost 2001; 85: 958-65.
53. Gorlinger K, Dirkmann D, Weber CF, Rahe-Meyer N, Hanke AA. Algorithms for transfusion and coagulation management in massive haemorrhage. Anasthesiologie & Intensivmedizin 2011; 52: 145-54.
54. Afshari AAA, Wikkelso A, Brok J, Moller AM, Wetterslev J. Thrombelastography (TEG) or thromboelastometry (ROTEM) to monitor haemotherapy versus usual care in patients with massive transfusion. Cochrane Database Syst Rev 2011; 3: CD007871.
55. Hartert H. Blutgerinnungsstudien mit der thrombelastographie; einem neuen untersuchungs verfahren. Klinische Wochenschrift 1948; 26: 577-83.
56. Mallett SV, Cox DJ. Thrombelastography. Br J Anaesth. 1992;69:307-13.
57. Coakley M, Reddy K, Mackie I, Mallett S. Transfusion triggers in orthotopic liver transplantation: a comparison of the thromboelastometry analyzer, the thromboelastogram, and conventional coagulation tests. J Cardiothorac Vasc Anesth 2006; 20: 548-53.
58. Reikvam H, Steien E, Hauge B, et al. Thrombelastography. Transfus Apheres Sci 2009; 40: 119-23.
59. Bolliger D, Seeberger MD, Tanaka KA. Principles and practice of thromboelastography in clinical coagulation management and transfusion practice. Transfus Med Rev 2011; 26: 1-13.
60. Ganter MT, Hofer CK. Coagulation monitoring: current techniques and clinical use of viscoelastic point-of-care coagulation devices. Anesth Analg 2008; 106: 1366-75.
61. Rugeri L, Levrat A, David JS, et al. Diagnosis of early coagulation abnormalities in trauma patients by rotation thrombelastography. J Thromb Haemost 2007; 5: 289-95.
62. Alexander DC, Butt WW, Best JD, et al. Correlation of thromboelastography with standard tests of anticoagulation in paediatric patients receiving extracorporeal life support. Thromb Res 2010; 125: 387-92.
63. Nascimento B, Al M, Callum J, et al. Vitamin K-dependent coagulation factor deficiency in trauma: a comparative analysis between international normalized ratio and thromboelastography. Transfusion 2011; 52: 7-13.
64. Hepner DL, Concepcion M, Bhavani-Shankar K. Coagulation status using thromboelastography in patients receiving warfarin prophylaxis and epidural analgesia. J Clin Anesth 2002; 14: 405-10.
65. Fries D, Haas T, Klingler A, et al. Efficacy of fibrinogen and prothrombin complex concentrate used to reverse dilutional coagulopathy-a porcine model. Br J Anaesth 2006; 97: 460-7.
66. Noval-Padillo JA, Leon-Justel A, Mellado-Miras P, et al. Introduction of fibrinogen in the treatment of hemostatic disorders during orthotopic liver transplantation: implications in the use of allogenic blood. Transpl Proc 2010; 42: 2973-4.
67. Lang T, Toller W, Gutl M, et al. Different effects of abciximab and cytochalasin D on clot strength in thrombelastography. J Thromb Haemost 2004; 2: 147-53.
68. Gunduz E, Akay OM, Bal C, Gulbas Z. Can thrombelastography be a new tool to assess bleeding risk in patients with idiopathic thrombocytopenic purpura? Platelets 2011; 22: 516-20.
69. Larsen OH, Ingerslev J, Sorensen B. Whole blood laboratory model of thrombocytopenia for use in evaluation of hemostatic interventions. Ann Hematol 2007; 86: 217-21.
70. Gorlinger K, Dirkmann D, Hanke AA, et al. First-line therapy with coagulation factor concentrates combined with point-of-care coagulation testing is associated with decreased allogeneic blood transfusion in cardiovascular surgery: a retrospective, single-center cohort study. Anesthesiology 2011; 115: 1179-91.
71. Fenger-Eriksen C, Moore GW, Rangarajan S, Ingerslev J, Sorensen B. Fibrinogen estimates are influenced by methods of measurement and hemodilution with colloid plasma expanders. Transfusion 2010; 50: 2571-6.
72. Molinaro RJ, Szlam F, Levy JH, Fantz CR, Tanaka KA. Low plasma fibrinogen levels with the Clauss method during anticoagulation with bivalirudin. Anesthesiology 2008; 109: 160-1.
73. Mittermayr M, Streif W, Haas T, et al. Hemostatic changes after crystalloid or colloid fluid administration during major orthopedic surgery: the role of fibrinogen administration. Anesth Analg 2007; 105: 905-17. table of contents.
74. Carroll RC, Craft RM, Chavez JJ, et al. Measurement of functional fibrinogen levels using the Thrombelastograph. J Clin Anesth 2008; 20: 186-90.
75. Solomon C, Sorensen B, Hochleitner G, et al. Comparison of whole blood fibrin-based clot tests in thrombelastography and thromboelastometry. Anesth Analg 2012; 114: 721-30.
76. Kupesiz A, Rajpurkar M, Warrier I, et al. Tissue plasminogen activator induced fibrinolysis: standardization of method using thromboelastography. Blood Coagul Fibrinolysis 2010; 21: 320-4.
77. Gallimore MJ, Harris SL, Tappenden KA, Winter M, Jones DW. Urokinase induced fibrinolysis in thromboelastography: a model for studying fibrinolysis and coagulation in whole blood. J Thromb Haemost 2005; 3: 2506-13.
78. Bolliger D, Szlam F, Levy JH, Molinaro RJ, Tanaka KA. Haemodilution-induced profibrinolytic state is mitigated by fresh-frozen plasma: implications for early haemostatic intervention in massive haemorrhage. Br J Anaesth 2010; 104: 318-25.
79. Rivard GE, Brummel-Ziedins KE, Mann KG, et al. Evaluation of the profile of thrombin generation during the process of whole blood clotting as assessed by thrombelastography. J Thromb Haemost 2005; 3: 2039-43.
80. Sorensen B, Johansen P, Christiansen K, Woelke M, Ingerslev J. Whole blood coagulation thrombelastographic profiles employing minimal tissue factor activation. J Thromb Haemost 2003; 1: 551-8.
81. Young G, Ebbesen LS, Viuff D, et al. Evaluation of thromboelastography for monitoring recombinant activated factor VII ex vivo in haemophilia A and B patients with inhibitors: a multicentre trial. Blood Coagul Fibrinolysis 2008; 19: 276-82.
82. Coppell JA, Thalheimer U, Zambruni A, et al. The effects of unfractionated heparin, low molecular weight heparin and danaparoid on the thromboelastogram (TEG): an in-vitro comparison of standard and heparinase-modified TEGs with conventional coagulation assays. Blood Coagul Fibrinolysis 2006; 17: 97-104.
83. White H, Sosnowski K, Bird R, Jones M, Solano C. The utility of thromboelastography in monitoring low molecular weight heparin therapy in the coronary care unit. Blood Coagul Fibrinolysis 2012; 23: 304-10.
84. McKee RF, Hodson S, Dawes J, Garden OJ, Carter DC. Plasma concentrations of endogenous heparinoids in portal hypertension. Gut 1992; 33: 1549-52.
85. Nelson A, Berkestedt I, Schmidtchen A, Ljunggren L, Bodelsson M. Increased levels of glycosaminoglycans during septic shock: relation to mortality and the antibacterial actions of plasma. Shock 2008; 30: 623-7.
86. Ostrowski SR, Johansson PI. Endothelial glycocalyx degradation induces endogenous heparinization in patients with severe injury and early traumatic coagulopathy. J Trauma Acute Care Surg 2012; 73: 60-6.
87. Kettner SC, Gonano C, Seebach F, et al. Endogenous heparin-like substances significantly impair coagulation in patients undergoing orthotopic liver transplantation. Anesth Analg 1998; 86: 691-5.
88. Montalto P, Vlachogiannakos J, Cox DJ, et al. Bacterial infection in cirrhosis impairs coagulation by a heparin effect: a prospective study. J Hepatol 2002; 37: 463-70.
89. Mancuso A, Fung K, Cox D, et al. Assessment of blood coagulation in severe liver disease using thromboelastography: use of citrate storage versus native blood. Blood Coagul Fibrinolysis 2003; 14: 211-16.
90. Papatheodoridis GV, Patch D, Webster GJ, et al. Infection and hemostasis in decompensated cirrhosis: a prospective study using thrombelastography. Hepatology 1999; 29: 1085-90.
91. Thalheimer U, Triantos C, Samonakis D, et al. Endogenous heparinoids in acute variceal bleeding. Gut 2005; 54: 310-11.
92. Chau TN, Chan YW, Patch D, et al. Thrombelasto-graphic changes and early rebleeding in cirrhotic patients with variceal bleeding. Gut 1998; 43: 267-71.
93. Thalheimer U, Triantos C, Samonakis D, Patch D, Burroughs AK. Heparin effect on thromboelastography after transjugular intrahepatic portosystemic shunt procedure. Scand J Gastroenterol 2009; 44: 1463-70.
94. Northup PG. Hypercoagulation in liver disease. Clin Liver Dis 2009; 13: 109-16.
95. Tsochatzis EA, Senzolo M, Germani G, Gatt A, Burroughs AK. Systematic review: portal vein thrombosis in cirrhosis. Aliment Pharmacol Ther 2010; 31: 366-74.
96. Tripodi A, Primignani M, Chantarangkul V, et al. An imbalance of pro- vs anti-coagulation factors in plasma from patients with cirrhosis. Gastroenterology 2009; 137: 2105-11.
97. Hickman IJ, Sullivan CM, Flight S, et al. Altered clot kinetics in patients with non-alcoholic fatty liver disease. Ann Hepatol 2009; 8: 331-8.
98. Cakir T, Cingi A, Yegen C. Coagulation dynamics and platelet functions in obstructive jaundiced patients. J Gastroenterol Hepatol 2009; 24: 748-51.
99. McCrath DJ, Cerboni E, Frumento RJ, Hirsh AL, Bennett-Guerrero E. Thromboelastography maximum amplitude predicts postoperative thrombotic complications including myocardial infarction. Anesth Analg 2005; 100: 1576-83.
100. Dai Y, Lee A, Critchley LAH, White PF. Does thromboelastography predict postoperative thromboembolic events? A systematic review of the literature. Anesth Analg 2009; 108: 734-42.
101. Munoz SJ, Rajender Reddy K, Lee W. The coagulopathy of acute liver failure and implications for intracranial pressure monitoring. Neurocrit Care 2008; 9: 103-7.
102. Todd Stravitz R, Lisman T, Luketic VA, et al. Minimal effects of acute liver injury/acute liver failure on hemostasis as assessed by thromboelastography. J Hepatol 2011; 56: 129-36.
103. Agarwal B, Wright G, Gatt A, et al. Evaluation of coagulation abnormalities in Acute Liver Failure. J. Hepatol 2012; 57: 780-6.
104. Herriman DJ, Mallett S. A comparison of baseline International Normalised Ratio (INR) and Thromboelastography (TEG) R times, and transfusion requirements for patients with fulminant hepatic failure undergoing Orthotopic Liver Transplant (OLT). Liver Transpl 2011; 17: S120-3.
105. Agarwal S, Senzolo M, Melikian C, Burroughs A, Mallett SV. The prevalence of a heparin-like effect shown on the thromboelastograph in patients undergoing liver transplantation. Liver Transpl 2008; 14: 855-60.
106. Senzolo M, Riddell A, Tuddenham E, Burroughs AK. Endogenous heparinoids contribute to coagulopathy in patients with liver disease. J Hepatol 2008; 48: 371-2.
107. Senzolo M, Sartori MT, Lisman T. Should we give thromboprophylaxis to patients with liver cirrhosis and coagulopathy? HPB (Oxford) 2009; 11: 459-64.
108. Francoz C, Belghiti J, Vilgrain V, et al. Splanchnic vein thrombosis in candidates for liver transplantation: usefulness of screening and anticoagulation. Gut 2005; 54: 691-7.
109. Kaneko J, Sugawara Y, Tamura S, et al. Coagulation and fibrinolytic profiles and appropriate use of heparin after living-donor liver transplantation. Clin Transplant 2005; 19: 804-9.
110. Senzolo M, Rodriguez-Castro KI, Rossetto V, et al. Increased anticoagulant response to low-molecular-weight heparin in plasma from patients with advanced cirrhosis. J Thromb Haemost 2012; 10: 1823-9.
111. Hirsh J, Warkentin TE, Shaughnessy SG, et al. Heparin and low-molecular-weight heparin: mechanisms of action, pharmacokinetics, dosing, monitoring, efficacy, and safety. Chest 2001; 119(Suppl 1): 64S-94S.
112. Bechmann LP, Sichau M, Wichert M, et al. Low-molecular-weight heparin in patients with advanced cirrhosis. Liver Int 2011; 31: 75-82.
113. Van PY, Cho SD, Underwood SJ, et al. Thrombelastography versus AntiFactor Xa levels in the assessment of prophylactic-dose enoxaparin in critically ill patients. J Trauma. 2009;66:1509-15; discussion 15-7.
114. Villa E, Camma C, Marietta M, et al. Enoxaparin prevents portal vein thrombosis and liver decompensation in patients with advanced cirrhosis. Gastroenterology. 2012;143: 1253-60 e1-4.
115. Wanless IR, Wong F, Blendis LM, et al. Hepatic and portal vein thrombosis in cirrhosis: possible role in development of parenchymal extinction and portal hypertension. Hepatology 1995; 21: 1238-47.
116. Stahl RL, Duncan A, Hooks MA, et al. A hypercoagulable state follows orthotopic liver transplantation. Hepatology 1990; 1: 553-8.
117. Lisman T, Porte RJ. Hepatic artery thrombosis after liver transplantation: more than just a surgical complication? Transpl Int 2009; 22: 162-4.
118. Ayala R, Martinez-Lopez J, Cedena T, et al. Recipient and donor thrombophilia and the risk of portal venous thrombosis and hepatic artery thrombosis in liver recipients. BMC Gastroenterol 2011; 11: 130.
119. Widen A, Rolando N, Manousou P, et al. Anticoagulation after liver transplantation: a retrospective audit and case-control study. Blood Coagul Fibrinolysis 2009; 20: 615-18.
120. Rautou PE, Douarin L, Denninger MH, et al. Bleeding in patients with Budd-Chiari syndrome. J Hepatol 2011; 54: 56-63.
121. James K, Bertoja E, O'Beirne J, Mallett S. Use of thromboelastography PlateletMapping (TM) to monitor antithrombotic therapy in a patient with Budd-Chiari syndrome. Liver Transpl 2010; 16: 38-41.